Overview

Telmisartan, Amlodipine and Flow Mediated Dilation

Status:
Unknown status
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To show superior effects of the combination Telmisartan and Amlodipine (T and A) vs Olmesartan and Hydrochlorothiazide (O and HCTZ) on endothelial dysfunction as measured by flow mediated dilation (FMD) in hypertensive at risk patients beyond bloodpressure BP (equal BP in both arms; target BP <140/90 mmHg (<130/80 mmHg for renally impaired and/ or diabetic patients). To investigate the effects of T and A vs O and HCTZ in reducing arterial stiffness and carotid atherosclerotic plaques.
Phase:
Phase 4
Details
Lead Sponsor:
Johannes Gutenberg University Mainz
Treatments:
Amlodipine
Hydrochlorothiazide
Olmesartan
Olmesartan Medoxomil
Telmisartan